mesalamine

(redirected from Apriso)
Also found in: Medical.

me·sal·a·mine

 (mə-săl′ə-mēn′)
n.
A salicylate drug derived from sulfasalazine, C7H7NO3, used primarily to treat inflammatory bowel disease.

Translations

mesalamine

(USAN), mesalazine (INN) n mesalamina, mesalazina (INN)
References in periodicals archive ?
ENPNewswire-August 1, 2019--BAUSCH HEALTH PROVIDES APRISO INTELLECTUAL PROPERTY LITIGATION UPDATE
Bausch Health (BHC) entered into a settlement agreement with Teva (TEVA) regarding the ongoing patent challenge to its branded ulcerative colitis drug Apriso, which posted 2018 U.S.
This is in contrast to Dassault's acquisition several years ago of Apriso and its MES portfolio, which is leveraged more for large manufacturing customers like Lockheed Martin or Saint-Gobain.
* Aminosalicylates: Sulfasalazine (Azulfidine), olsalazine (Dipentum), mesalamine (Apriso, Asacol), balsalazide (Colazol)
* Aminosalicylates, such as mesalamine (Lialda), mesalamine extended-release (Apriso), olsalazine (Dipentum), and balsalazide (Colazal)
To get a sense of this transformation we talk with Fred Thomas, DELMIA Apriso Director, Discrete Manufacturing Industries at Dassault Systemes (apriso.com).
The company will invest $15 million in its Steinbach facility, including $7 million in upgrades to product manufacturing technology and $8 million for the transfer of North American production of Xifaxan and Apriso. These drugs are used to treat hepatic encephalopathy and irritable bowel syndrome, and ulcerative colitis.
Ortems complements Dassault Systemes' DELMIA brand applications, including DELMIA Apriso, which offer a unified experience to all users in digital manufacturing, manufacturing operations management, and supply chain planning and operations, built on a single referential data model.
It will invest USD15m at Steinbach by the end of 2016, including USD7m in upgrades to product manufacturing technology and USD8m for the transfer of North American production of Xifaxan (rifaximin) and Apriso (mesalamine).
Under the expansion plans, the company will invest USD15m in its Steinbach, Manitoba facility by the end of 2016, including USD7m in upgrades to product manufacturing technology and USD8m for the transfer of North American production of Xifaxan (rifaximin) and Apriso (mesalamine).
Prior to joining Skelia, Piotr has held senior positions in leading technology companies InterCard, IBM, and Apriso.